Kraig Biocraft Laboratories Provides Production Update on Recombinant Spider Silk Operations
Rhea-AI Summary
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced significant progress in its recombinant spider silk production operations. The company is currently executing its largest-ever production batch, with the first half already completed and cocoons being prepared for silk reeling. The second half is expected to finish within 14 days.
The current production run represents a milestone as the first simultaneous batches of BAM-1 produced in their newest facilities. Initial results show promising performance of the BAM-1 hybrids and effectiveness of the expanded infrastructure. The company has also completed production of all BAM-1 hybrid eggs scheduled for release next month, ensuring consistent supply for upcoming production cycles.
According to CEO Kim Thompson, this successful execution of simultaneous production demonstrates their technology's scalability from batch processing to continuous flow manufacturing.
Positive
- Successfully executing largest-ever production batch of spider silk
- Demonstrated capability for simultaneous production batches
- Completed production of BAM-1 hybrid eggs for next month's operations
- Successfully scaled up from batch processing to continuous flow manufacturing
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, KBLB declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
ANN ARBOR, Mich., April 21, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), a world leader in spider silk technology*, is pleased to provide an update on recombinant spider silk production. The Company continues to increase its production output and is now in the middle of its largest-ever batch of recombinant spider silk production.
Kraig Labs can now report that it has successfully completed the first half of its current production batch and those spider silk cocoons are being prepared for reeling into finished silk. This second half of this production cycle is expected to be complete in the next 14 days.
This current production run marks a significant milestone, as the first simultaneous batches of BAM-1 produced in the Company's newest facilities. The initial results have been highly encouraging, demonstrating the robustness of the BAM-1 hybrids and the efficiency of the expanded production infrastructure. The concurrent operation of multiple batches has proceeded smoothly, underscoring the scalability and reliability of the Company’s production model.
In addition to the progress in silk production, Kraig Labs has completed the production of all BAM-1 hybrid eggs designated for release over the next month. This achievement ensures a steady supply of high-quality hybrids for upcoming production cycles, aligning with the Company's strategic objectives and production goals for 2025.
"The successful execution of simultaneous production batches in our new facilities demonstrates the scalability of our technology from batch processing to continuous flow manufacturing," said Kim Thompson, Founder and CEO of Kraig Labs. "With this cycle nearing completion and the next generation of BAM-1 hybrids already prepared, we are in a strong position to rapidly accelerate the growth and commercialization of our spider silk."
Kraig Labs remains committed to advancing the commercialization of its eco-friendly and high-performance spider silk fibers. The Company will continue to provide updates as it progresses toward its production and commercialization goals.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
FAQ
What is the current status of KBLB's spider silk production batch?
How is KBLB's BAM-1 hybrid performing in the new facilities?
What production milestone has KBLB achieved with BAM-1 hybrid eggs?
How is KBLB transitioning from batch processing to continuous manufacturing?
